vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($349.1M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -10.8%, a 21.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 15.6%). PROCORE TECHNOLOGIES, INC. produced more free cash flow last quarter ($109.2M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 13.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
ANIP vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $349.1M |
| Net Profit | $27.5M | $-37.6M |
| Gross Margin | — | 80.1% |
| Operating Margin | 14.1% | -12.3% |
| Net Margin | 11.1% | -10.8% |
| Revenue YoY | 29.6% | 15.6% |
| Net Profit YoY | 367.5% | 39.6% |
| EPS (diluted) | $1.14 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $349.1M | ||
| Q3 25 | $227.8M | $338.9M | ||
| Q2 25 | $211.4M | $323.9M | ||
| Q1 25 | $197.1M | $310.6M | ||
| Q4 24 | $190.6M | $302.0M | ||
| Q3 24 | $148.3M | $295.9M | ||
| Q2 24 | $138.0M | $284.3M | ||
| Q1 24 | $137.4M | $269.4M |
| Q4 25 | $27.5M | $-37.6M | ||
| Q3 25 | $26.6M | $-9.1M | ||
| Q2 25 | $8.5M | $-21.1M | ||
| Q1 25 | $15.7M | $-33.0M | ||
| Q4 24 | $-10.3M | $-62.3M | ||
| Q3 24 | $-24.2M | $-26.4M | ||
| Q2 24 | $-2.3M | $-6.3M | ||
| Q1 24 | $18.2M | $-11.0M |
| Q4 25 | — | 80.1% | ||
| Q3 25 | — | 79.7% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 79.1% | ||
| Q4 24 | — | 81.2% | ||
| Q3 24 | — | 81.4% | ||
| Q2 24 | — | 83.1% | ||
| Q1 24 | — | 83.0% |
| Q4 25 | 14.1% | -12.3% | ||
| Q3 25 | 15.9% | -4.4% | ||
| Q2 25 | 6.6% | -9.3% | ||
| Q1 25 | 13.3% | -11.7% | ||
| Q4 24 | -2.3% | -21.9% | ||
| Q3 24 | -13.8% | -12.3% | ||
| Q2 24 | 3.7% | -5.2% | ||
| Q1 24 | 14.8% | -7.0% |
| Q4 25 | 11.1% | -10.8% | ||
| Q3 25 | 11.7% | -2.7% | ||
| Q2 25 | 4.0% | -6.5% | ||
| Q1 25 | 8.0% | -10.6% | ||
| Q4 24 | -5.4% | -20.6% | ||
| Q3 24 | -16.3% | -8.9% | ||
| Q2 24 | -1.7% | -2.2% | ||
| Q1 24 | 13.2% | -4.1% |
| Q4 25 | $1.14 | $-0.25 | ||
| Q3 25 | $1.13 | $-0.06 | ||
| Q2 25 | $0.36 | $-0.14 | ||
| Q1 25 | $0.69 | $-0.22 | ||
| Q4 24 | $-0.45 | $-0.42 | ||
| Q3 24 | $-1.27 | $-0.18 | ||
| Q2 24 | $-0.14 | $-0.04 | ||
| Q1 24 | $0.82 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $768.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.3B |
| Total Assets | $1.4B | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $768.5M | ||
| Q3 25 | $262.6M | $684.0M | ||
| Q2 25 | $217.8M | $620.9M | ||
| Q1 25 | $149.8M | $566.7M | ||
| Q4 24 | $144.9M | $775.4M | ||
| Q3 24 | $145.0M | $756.9M | ||
| Q2 24 | $240.1M | $735.4M | ||
| Q1 24 | $228.6M | $744.6M |
| Q4 25 | $540.7M | $1.3B | ||
| Q3 25 | $505.8M | $1.2B | ||
| Q2 25 | $436.8M | $1.2B | ||
| Q1 25 | $418.6M | $1.2B | ||
| Q4 24 | $403.7M | $1.3B | ||
| Q3 24 | $405.9M | $1.3B | ||
| Q2 24 | $455.8M | $1.3B | ||
| Q1 24 | $452.0M | $1.2B |
| Q4 25 | $1.4B | $2.2B | ||
| Q3 25 | $1.4B | $2.1B | ||
| Q2 25 | $1.3B | $2.0B | ||
| Q1 25 | $1.3B | $1.9B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.0B | ||
| Q2 24 | $920.8M | $2.0B | ||
| Q1 24 | $914.5M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $114.9M |
| Free Cash FlowOCF − Capex | $29.1M | $109.2M |
| FCF MarginFCF / Revenue | 11.8% | 31.3% |
| Capex IntensityCapex / Revenue | 0.5% | 1.6% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $282.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $114.9M | ||
| Q3 25 | $44.1M | $88.5M | ||
| Q2 25 | $75.8M | $30.8M | ||
| Q1 25 | $35.0M | $66.0M | ||
| Q4 24 | $15.9M | $29.1M | ||
| Q3 24 | $12.5M | $39.3M | ||
| Q2 24 | $17.4M | $58.7M | ||
| Q1 24 | $18.3M | $69.1M |
| Q4 25 | $29.1M | $109.2M | ||
| Q3 25 | $38.0M | $83.1M | ||
| Q2 25 | $71.8M | $27.9M | ||
| Q1 25 | $32.5M | $62.0M | ||
| Q4 24 | $13.5M | $17.4M | ||
| Q3 24 | $7.7M | $35.7M | ||
| Q2 24 | $13.0M | $56.8M | ||
| Q1 24 | $13.7M | $67.1M |
| Q4 25 | 11.8% | 31.3% | ||
| Q3 25 | 16.7% | 24.5% | ||
| Q2 25 | 34.0% | 8.6% | ||
| Q1 25 | 16.5% | 20.0% | ||
| Q4 24 | 7.1% | 5.8% | ||
| Q3 24 | 5.2% | 12.1% | ||
| Q2 24 | 9.4% | 20.0% | ||
| Q1 24 | 10.0% | 24.9% |
| Q4 25 | 0.5% | 1.6% | ||
| Q3 25 | 2.7% | 1.6% | ||
| Q2 25 | 1.9% | 0.9% | ||
| Q1 25 | 1.3% | 1.3% | ||
| Q4 24 | 1.3% | 3.9% | ||
| Q3 24 | 3.2% | 1.2% | ||
| Q2 24 | 3.2% | 0.7% | ||
| Q1 24 | 3.3% | 0.8% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
